PER-065-08已完成未知
A Randomised, Double Blind, Placebo Controlled, Phase IIb Dose Ranging Study (With Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 75（—）
入选标准
- •Provide informed consent (including consent for the PK subgroup, as applicable).
- •Be male or female over 18 years of age. Note: Women with pregnancy potential can be included only if highly effective contraceptive methods are used (see Section 3.3.4 and Appendix K) and if patients are fully aware of the information regarding the possibility of reproductive toxicity according to it is detailed in the informed consent form. Men who participate in the study should agree to abstain from having sex for procreative purposes during the study and for 12 weeks after the last dose of study medication.
- •Diagnosis of RA after 16 years of age according to the revised criteria (1987) American Collegue of Rheumatology.
- •Have active RA defined as follows: -> 4 swollen joints and> 6 tender / painful joints and: ESR> 28 mm / h or CRP> 10 mg / L.
- •Have at least one of the following items: - Documented background of positive rheumatoid factor - Current presence of rheumatoid factor - Basal radiographic erosion - Presence of anti-citrullinated cyclic peptide antibodies (anti-CCP) in serum.
- •Oral, subcutaneous or intramuscular methotrexate for a minimum of 6 months prior to randomization. The dose and means of administration of methotrexate should have been stable between 5 mg and 25 mg per week for a minimum of 6 weeks prior to randomization.
排除标准
- •Pregnant or lactating women (restrictions and procedures related to managing the risk of pregnancy / conception for men and women are set out in Sections 3.3.4 and 9.4).
- •Any systemic inflammatory affection besides RA that may interfere with the interpretation of the outcome data (among other examples we can mention polymyalgia rheumatica, gigantocellular arteritis [including temporal], reactive arthritis).
- •Current conditions with chronic pain, including fibromyalgia syndromes and chronic fatigue.
- •Functional Class IV of the American College of Rheumatology or in a wheelchair / confined to the bed.
- •Patients unable to comply with locally approved product information for etanercept. Note: any patient selected to receive etanercept will be confirmed as negative for LTBI prior to the start of treatment. In the event that the patient had a negative TB test in the month prior to Visit 1, the result of that analysis will prevail and the analysis should not be repeated. Patients who obtain positive results in the analysis should not continue, see Section 3.3.5.1).
- •Patients who previously did not respond to treatment with more than 1 biological agent.
- •Patients who, in the investigator´s opinion, have active TB as defined by clinical history and / or chest x-ray.
- •Patients who do not meet or are unlikely to comply with restrictions regarding the use of prior and concomitant medications as set forth in Section 3.7.
- •Clinical or biochemical evidence of active infections with hepatitis B or hepatitis C (carriers may be included, ie those who have positive serology but have no evidence of active disease).
- •The values of aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin> 2 x upper limit to normal (ULN) in Visit 1.
- •History of excessive alcohol consumption or chronic illness produced by it.
- •Patients who, at the investigator´s discretion, have a higher risk of developing ventricular arrhythmias
- •Chronic or acute kidney disease-patients may be included if the plasma / serum creatinine is within the normal range or, if abnormal, the calculated GFR (using the original Cockroft-Gault formula) or measured should be> 50 mL / min (see Appendix G).
- •History of cancer or neoplastic pathology, except squamous or basal cell carcinoma successfully treated with> 5 years old.
- •Any other clinically significant disorder or disease, which, in the investigator´s judgment, (by its nature or insufficiently controlled) may pose a risk to the patient due to participation in the study, or may influence the results of the study. study, or the patient´s ability to participate in the study, including chronic liver disease and the important history of recurrent infections.
- •Be part of the planning and conduct of the study (applies to both AstraZeneca staff and the staff of the study center).
- •Previous enrollment in the present study.
- •Recent participation in any clinical study involving any compound under investigation within 3 months prior to the randomization or 5 half lives of the product under investigation (the most extensive period). Patients who participate in non-drug methodology studies (whether invasive or not) can be included immediately, at the investigator´s discretion.
- •Patients who, in the opinion of the researcher, should not participate in the study.
研究者
相似试验
已完成
2 期
A Randomized, Double Blind, Placebo Controlled, Phase 2a Study to Assess the Clinical Efficacy of ISIS 721744, a Second Generation Ligand Conjugated Antisense Inhibitor of Prekallikrein, in Patients with Hereditary AngioedemaHereditary angioedemaNL-OMON49723Ionis Pharmaceuticals, Inc.8
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic AdenocarcinomaEUCTR2007-004102-27-NLSciClone Pharmaceuticals, Inc.153
进行中（未招募）
1 期
This is a randomized, double-blind, Placebo controlled trial to evaluate the efficacy of ISIS 721744 in Patients with Hereditary AngioedemaMedDRA version: 20.0Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary AngioedemaEUCTR2019-001044-22-GBIonis Pharmaceuticals, Inc.24
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic AdenocarcinomaEUCTR2007-004102-27-HUSciClone Pharmaceuticals, Inc.153
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinomametastatic pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableEUCTR2007-004102-27-DESciClone Pharmaceuticals, Inc.153